December 14, 2017 - 4:31 p.m.
Gilead Sciences Announces That John C. Martin, PhD Will Transition From Executive Chairman to Chairman of the Board of Directors
Printer Friendly Version 
December 11, 2017 - 7:31 p.m.
Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
Printer Friendly Version 
December 10, 2017 - 10:31 a.m.
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
Printer Friendly Version 
December 07, 2017 - 5:02 p.m.
Gilead Sciences and Kite to Acquire Cell Design Labs
Printer Friendly Version 
December 04, 2017 - 6:31 a.m.
Gilead Announces 10-Year, $100 Million Commitment to Address the HIV/AIDS Epidemic in the Southern United States
Printer Friendly Version 
November 22, 2017 - 9:00 a.m.
Gilead Sciences to Present at the Nasdaq 37th Investor Program on Wednesday, December 6
Printer Friendly Version 
October 26, 2017 - 4:04 p.m.
Gilead Sciences Announces Fourth Quarter 2017 Dividend
Printer Friendly Version 
October 26, 2017 - 4:02 p.m.
Gilead Sciences Announces Third Quarter 2017 Financial Results
Printer Friendly Version 
October 25, 2017 - 11:24 a.m.
Kite Pharma to Present at the Citi 9th Annual Biotech Conference on Wednesday, September 3
Printer Friendly Version 
October 24, 2017 - 4:02 p.m.
Gilead Sciences to Present at the Credit Suisse 26th Annual Healthcare Conference on Tuesday, November 7
Printer Friendly Version 
October 24, 2017 - 8:37 a.m.
Gilead Announces Phase 2 Results for GS-0976 in Nonalcoholic Steatohepatitis (NASH)
Printer Friendly Version 
October 20, 2017 - 8:04 a.m.
Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®
Printer Friendly Version 
October 18, 2017 - 5:44 p.m.
Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy
Printer Friendly Version 
October 17, 2017 - 8:32 a.m.
Gilead Sciences Announces Promotion of Alessandro Riva to Executive Vice President, Oncology Therapeutics
Printer Friendly Version 
October 16, 2017 - 8:01 a.m.
Gilead Awards $7.5 Million in Second Round of Grants to Advance HIV Cure Research
Printer Friendly Version 
October 12, 2017 - 4:02 p.m.
Gilead Sciences to Release Third Quarter 2017 Financial Results on Thursday, October 26, 2017
Printer Friendly Version 
October 04, 2017 - 8:02 a.m.
Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched to Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide From Boosted Protease Inhibitor-Based Regimens
Printer Friendly Version 
October 04, 2017 - 3:02 a.m.
Gilead Announces New License Agreement With the Medicines Patent Pool for Access to Bictegravir
Printer Friendly Version 
October 03, 2017 - 8:46 a.m.
Gilead Sciences Completes Acquisition of Kite Pharma, Inc.
Printer Friendly Version 
October 03, 2017 - 8:01 a.m.
Gilead Sciences Completes Tender Offer for All Outstanding Shares of Kite Pharma, Inc.
Printer Friendly Version 
September 27, 2017 - 4:31 p.m.
Kevin Young CBE, Gilead’s Chief Operating Officer, to Retire
Printer Friendly Version 
September 26, 2017 - 12:08 p.m.
Gilead Sciences and Kite Pharma Announce Expiration of Hart-Scott-Rodino Waiting Period
Printer Friendly Version 
September 26, 2017 - 8:32 a.m.
Gilead Sciences and Kite Pharma Announce Expiration of Hart-Scott-Rodino Waiting Period
Printer Friendly Version 
September 25, 2017 - 7:56 a.m.
China Food and Drug Administration Approves Gilead’s Sovaldi® (Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Infection
Printer Friendly Version 
September 14, 2017 - 6:47 p.m.
Gilead Prices $3 Billion of Senior Unsecured Notes
Printer Friendly Version 
September 05, 2017 - 4:02 p.m.
Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Monday, September 11
Printer Friendly Version 
September 01, 2017 - 9:01 a.m.
Gilead Sciences to Present at Citi’s 12th Annual Biotech Conference on Wednesday, September 6
Printer Friendly Version 
August 28, 2017 - 12:51 p.m.
Gilead Sciences to Acquire Kite Pharma for $11.9 Billion
Printer Friendly Version 
August 28, 2017 - 4:00 a.m.
Gilead Sciences to Acquire Kite Pharma for $11.9 Billion
Printer Friendly Version 
August 17, 2017 - 1:08 p.m.
Kite Highlights Publication from the National Cancer Institute Demonstrating Responses in Patients with Metastatic Solid Tumors Treated with T Cell Receptor (TCR) Therapy Targeting MAGE A3
Printer Friendly Version 
August 10, 2017 - 4:02 p.m.
Gilead Announces U.S. FDA Priority Review Designation for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
Printer Friendly Version 
August 08, 2017 - 2:32 p.m.
Kite Submits Investigational New Drug (IND) Application for KITE-585, Anti-BCMA CAR-T Therapy Candidate for Multiple Myeloma
Printer Friendly Version 
August 08, 2017 - 2:21 p.m.
Kite Reports Second Quarter 2017 Financial Results
Printer Friendly Version 
August 07, 2017 - 2:45 p.m.
Kite Announces Initiation of Axicabtagene Ciloleucel CAR-T Clinical Program in the European Union
Printer Friendly Version 
August 03, 2017 - 2:49 p.m.
Kite Announces Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma (SCHOLAR-1) Outcomes Published in the Journal BLOOD
Printer Friendly Version 
August 02, 2017 - 2:52 p.m.
Kite Doses First Patient in the Phase 2 Trial of Axicabtagene Ciloleucel in Indolent B-Cell Non-Hodgkin Lymphoma (ZUMA-5)
Printer Friendly Version 
August 01, 2017 - 4:02 p.m.
U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV
Printer Friendly Version 
August 01, 2017 - 3:00 p.m.
Kite to Report Second Quarter 2017 Financial Results on August 8, 2017
Printer Friendly Version 
August 01, 2017 - 2:57 p.m.
Kite to Present at August 2017 Investor Conference
Printer Friendly Version 
July 31, 2017 - 11:20 a.m.
Kite Files the Industry's First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel
Printer Friendly Version 
July 28, 2017 - 5:47 a.m.
European Commission Grants Marketing Authorization for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Genotypes of Chronic Hepatitis C
Printer Friendly Version 
July 26, 2017 - 4:04 p.m.
Gilead Sciences Announces Third Quarter 2017 Dividend
Printer Friendly Version 
July 26, 2017 - 4:02 p.m.
Gilead Sciences Announces Second Quarter 2017 Financial Results
Printer Friendly Version 
July 24, 2017 - 5:07 a.m.
Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
Printer Friendly Version 
July 20, 2017 - 11:22 a.m.
Kite Highlights Durable Complete Remissions Up to 56+ Months in Patients with Chemorefractory Aggressive Non-Hodgkin Lymphoma (NHL) after Anti-CD19 CAR T-Cell Therapy at the National Cancer Institute
Printer Friendly Version 
July 18, 2017 - 1:36 p.m.
U.S. Food and Drug Administration Approves Gilead’s Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-Treatment of Adults with Chronic Hepatitis C Virus
Printer Friendly Version 
July 13, 2017 - 6:59 a.m.
European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
Printer Friendly Version 
July 12, 2017 - 5:01 p.m.
Gilead Sciences to Release Second Quarter 2017 Financial Results on Wednesday, July 26, 2017
Printer Friendly Version 
June 28, 2017 - 11:26 a.m.
U.S. Patent Office to Confirm Kite's Seminal Eshhar CAR-T Patent
Printer Friendly Version 
June 27, 2017 - 11:28 a.m.
Kite Named to the MIT Technology Review's Annual 50 Smartest Companies List in Recognition for its Leadership in Establishing CAR-T Therapy
Printer Friendly Version 
June 23, 2017 - 7:36 a.m.
European CHMP Adopts Positive Opinion for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Chronic Hepatitis C Genotypes
Printer Friendly Version 
June 12, 2017 - 8:17 a.m.
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV Treatment
Printer Friendly Version 
June 06, 2017 - 11:33 a.m.
Kite to Present at June 2017 Investor Conferences
Printer Friendly Version 
June 05, 2017 - 11:34 a.m.
Kite Reports 73 Percent of Patients Achieved MRD Negative Complete Remission in Updated Analysis From Phase 1 ZUMA-3 CAR-T Trial of KTE-C19 in Adult Patients With High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia
Printer Friendly Version 
June 01, 2017 - 5:01 p.m.
Gilead Sciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15
Printer Friendly Version 
May 30, 2017 - 5:01 p.m.
Gilead Sciences to Present at the 37th Annual William Blair Growth Stock Conference on Tuesday, June 13
Printer Friendly Version 
May 30, 2017 - 8:31 a.m.
Gilead’s Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies
Printer Friendly Version 
May 26, 2017 - 11:36 a.m.
Kite Receives U.S. Food and Drug Administration Priority Review for Axicabtagene Ciloleucel
Printer Friendly Version 
May 17, 2017 - 11:38 a.m.
Kite Announces Presentations on Its Lead CAR-T Therapy Development Program at the 2017 American Society of Clinical Oncology Annual Meeting
Printer Friendly Version 
May 08, 2017 - 11:40 a.m.
Kite Reports First Quarter Financial Results
Printer Friendly Version 
May 04, 2017 - 5:01 p.m.
Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Thursday, May 18
Printer Friendly Version 
May 02, 2017 - 4:03 p.m.
Gilead Sciences Announces Second Quarter 2017 Dividend
Printer Friendly Version 
May 02, 2017 - 4:03 p.m.
Gilead Sciences Announces First Quarter 2017 Financial Results
Printer Friendly Version 
May 01, 2017 - 11:47 a.m.
Kite to Report First Quarter 2017 Financial Results on May 8, 2017
Printer Friendly Version 
April 21, 2017 - 12:01 p.m.
Gilead Announces Scientific Presentations Demonstrating Efficacy of Harvoni® (Ledipasvir/Sofosbuvir) in Special Patient Populations With HCV Infection
Printer Friendly Version 
April 21, 2017 - 4:31 a.m.
Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017
Printer Friendly Version 
April 20, 2017 - 12:01 p.m.
Gilead Presents Data at the International Liver Congress™ 2017 Supporting the Efficacy and Safety of Vemlidy in Patients with Chronic Hepatitis B After 96 Weeks, and Also After Switching From Viread
Printer Friendly Version 
April 20, 2017 - 9:31 a.m.
Gilead to Present Clinical and Preclinical Data on Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017
Printer Friendly Version 
April 18, 2017 - 5:02 p.m.
Gilead Sciences to Release First Quarter 2017 Financial Results on Tuesday, May 2, 2017
Printer Friendly Version 
April 07, 2017 - 10:11 a.m.
U.S. FDA Approves New Indications for Harvoni® and Sovaldi® in Pediatric Patients 12 Years and Older with Chronic Hepatitis C Infection
Printer Friendly Version 
April 06, 2017 - 11:49 a.m.
Kite Wins ‘Clinical Trial Result of the Year' for its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Awards
Printer Friendly Version 
April 04, 2017 - 11:50 a.m.
Kite Presents Promising Preclinical Data from KITE-585, a Fully Human Anti-BCMA CAR T-Cell Product Candidate at the 2017 American Association of Cancer Research (AACR) Annual Meeting
Printer Friendly Version 
April 02, 2017 - 11:52 a.m.
Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 American Association of Cancer Research Annual Meeting
Printer Friendly Version 
March 31, 2017 - 11:53 a.m.
Kite Completes Submission of U.S. Biologics License Application (BLA) for Axicabtagene Ciloleucel as the First CAR-T Therapy for the Treatment of Patients With Aggressive Non-Hodgkin Lymphoma (NHL)
Printer Friendly Version 
March 30, 2017 - 11:55 a.m.
Kite to Present Two Plenary Presentations from the ZUMA-1 Pivotal Trial of Axicabtagene Ciloleucel at the 2017 American Association of Cancer Research Annual Meeting
Printer Friendly Version 
March 16, 2017 - 11:56 a.m.
Kite Announces Appointment of Renowned Cancer Researcher, Owen N. Witte, M.D., to its Board of Directors
Printer Friendly Version 
March 14, 2017 - 11:58 a.m.
Kite Pharma Highlights Publication from the National Cancer Institute Demonstrating Durable Complete Remissions in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy and Anti-CD19 CAR T-Cell Therapy
Printer Friendly Version 
March 08, 2017 - 11:59 a.m.
Kite Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Printer Friendly Version 
March 06, 2017 - 12:11 p.m.
Kite to Present at March 2017 Investor Conferences
Printer Friendly Version 
March 05, 2017 - 12:12 p.m.
Richard L. Wang Named Chief Executive Officer of Fosun Kite Biotechnology Co., Ltd., a Joint Venture to Lead Development of Axicabtagene Ciloleucel and Other Engineered T-Cell Therapies for Treatment of Cancers in China
Printer Friendly Version 
March 02, 2017 - 12:14 p.m.
Kite Announces Commencement of Public Offering of Common Stock
Printer Friendly Version 
March 02, 2017 - 12:13 p.m.
Kite Announces Pricing of Public Offering of Common Stock
Printer Friendly Version 
February 28, 2017 - 5:01 p.m.
Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 14
Printer Friendly Version 
February 28, 2017 - 12:16 p.m.
Kite Announces Positive Topline Primary Results of Axicabtagene Ciloleucel from First Pivotal CAR-T Trial in Patients with Aggressive Non-Hodgkin Lymphoma
Printer Friendly Version 
February 28, 2017 - 12:15 p.m.
Kite Reports Fourth Quarter and Full Year 2016 Financial Results
Printer Friendly Version 
February 27, 2017 - 12:17 p.m.
Kite to Report Fourth Quarter and Full Year 2016 Financial Results on February 28, 2017
Printer Friendly Version 
February 14, 2017 - 7:01 p.m.
Gilead Announces 144-Week Data Evaluating Safety and Efficacy of Genvoya® for Treatment of HIV-1 in Treatment-Naïve Adults
Printer Friendly Version 
February 13, 2017 - 6:47 p.m.
Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors
Printer Friendly Version 
February 13, 2017 - 6:47 p.m.
Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV
Printer Friendly Version 
February 08, 2017 - 7:18 p.m.
Gilead Sciences to Present at the RBC Capital Markets 2017 Global Healthcare Conference on Wednesday, February 22
Printer Friendly Version 
February 07, 2017 - 4:04 p.m.
Gilead Sciences Announces 10 Percent Increase in First Quarter 2017 Dividend
Printer Friendly Version 
February 07, 2017 - 4:02 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results
Printer Friendly Version 
January 24, 2017 - 5:02 p.m.
Gilead Sciences to Release Fourth Quarter and Full Year 2016 Financial Results on Tuesday, February 7, 2017
Printer Friendly Version 
January 20, 2017 - 5:49 a.m.
European Medicines Agency Validates Gilead’s Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)
Printer Friendly Version 
January 11, 2017 - 6:53 a.m.
European Commission Grants Marketing Authorization for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection
Printer Friendly Version 
January 10, 2017 - 12:19 p.m.
Kite Pharma and Fosun Pharma Establish Joint Venture in China to Develop and Commercialize Autologous T-Cell Therapies to Treat Cancer
Printer Friendly Version 
January 10, 2017 - 9:01 a.m.
Gilead Awards More Than $22 Million in Grants to Support HIV Cure Research
Printer Friendly Version 
January 09, 2017 - 12:20 p.m.
Kite Pharma Establishes a Strategic Partnership With Daiichi Sankyo to Develop and Commercialize Axicabtagene Ciloleucel (KTE-C19) in Japan
Printer Friendly Version 
January 05, 2017 - 12:33 p.m.
Kite Pharma Enhances Commercial Expertise with the Appointment of Ian T. Clark to its Board of Directors
Printer Friendly Version 
January 04, 2017 - 12:35 p.m.
Kite Pharma to Present at the 35th Annual J.P. Morgan Healthcare Conference
Printer Friendly Version 
January 03, 2017 - 4:31 p.m.
Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head
Printer Friendly Version 
January 03, 2017 - 12:36 p.m.
Kite Pharma Submits Investigational New Drug (IND) Application for KITE-718, an Investigational Next Generation T-Cell Receptor (TCR) Therapy Targeting Cancer Antigens MAGE A3 and MAGE A6
Printer Friendly Version 
NASDAQ (US Dollar)
$75.57
 Stock is Up 1.23 (1.65%)
Data as of 12/15/17 4:15 p.m. ET
Minimum 20 minute delay
Refresh Quote